Rosetta Genomics Ltd (ROSGQ) Fair Value & Analysis

Healthcare · US · Market cap $592

Below-average quality, currently priced close to our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.

How to read this chart

60‑month range $0.0001 – $2.84 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Rosetta Genomics Ltd (ROSGQ) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at $2.9M. Revenue grew 115.3% year over year. The balance sheet holds a net cash position of $2.4M. Fundamentals as of Aug 21, 2026

The share trades about 50% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 0%, ROSGQ screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid …

Full company description

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2012 – FY2016 · reported fiscal years

Rosetta Genomics Ltd reported revenue of $9.2M in FY2016 versus $201K in FY2012, a compound +160.3%/yr. Reported net income was −$16.2M in FY2016.

Watch ROSGQ: get an alert when its fair value changes →

Peer Group

Diagnostics & Research · 138 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.